The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer following treatment with first-line platinum-based chemotherapy in combination with bevacizumab. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target raised to 16,000 GBp from 14,000 GBp at JPMorgan
- JPMorgan ups AstraZeneca target, adds to Analyst Focus List
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- Salesforce’s Agentforce selected by AstraZeneca as unified global platform